Literature DB >> 8186153

Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting.

H R Franklin1, G P Simonetti, A C Dubbelman, W W ten Bokkel Huinink, B G Taal, G Wigbout, I A Mandjes, O B Dalesio, N K Aaronson.   

Abstract

BACKGROUND: The Common Toxicity Criteria adopted by the NCI in the USA for grading toxicity in cancer clinical trials have been compared to the WHO scoring system which is still in use in Europe. PATIENTS &
METHODS: Sixty-six patients undergoing emetic chemotherapy at the Netherlands Cancer Institute completed questionnaires, 32 according to the WHO criteria and 34 to the Common Toxicity Criteria, on the severity, frequency and duration of gastro-intestinal toxicity. Their answers were then compared to the scores coded by research nurses and physicians. The nurses coded acute toxicity when the patients were discharged, and the doctors coded overall toxicity when the patients returned for the subsequent course of chemotherapy. To evaluate the coding systems, an estimate was made of the percentage agreement between the patients' answers and the nurses' and doctors' ratings.
RESULTS: The percentage agreement of the Common Toxicity Criteria with the patients' own experiences of nausea and vomiting was considerably better than that of the WHO score. The Gamma statistic confirmed this. The Common Toxicity Criteria have now been adopted for grading toxicity in studies of the Early Clinical Trials Group of the EORTC and are recommended for use in other clinical trials.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186153     DOI: 10.1093/oxfordjournals.annonc.a058760

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  17 in total

1.  Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study.

Authors:  Julie Wang; Sangita P Patil; Nan Yang; Jimmy Ko; Joohee Lee; Sally Noone; Hugh A Sampson; Xiu-Min Li
Journal:  Ann Allergy Asthma Immunol       Date:  2010-07       Impact factor: 6.347

2.  Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients.

Authors:  K Mystakidou; E Katsouda; A Linou; E Parpa; V Kouloulias; V Nikolaou; L Vlahos
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Combination treatment of captopril and prazosin to treat patients with gestational hypertension.

Authors:  Bo Hong; Xiang Ding; Hongmei Iia; Jianmei Zhang
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

4.  Clinical characteristics of infant neuroblastoma and a summary of treatment outcome.

Authors:  Yi Zhang; Dongsheng Huang; Weiling Zhang; Suoqin Tang; Tao Han; Xia Zhu; Aiping Liu; Tian Zhi
Journal:  Oncol Lett       Date:  2016-11-04       Impact factor: 2.967

5.  Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study.

Authors:  Sangita P Patil; Julie Wang; Ying Song; Sally Noone; Nan Yang; Sylvan Wallenstein; Hugh A Sampson; Xiu-Min Li
Journal:  J Allergy Clin Immunol       Date:  2011-07-26       Impact factor: 10.793

Review 6.  The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.

Authors:  Thomas M Atkinson; Sean J Ryan; Antonia V Bennett; Angela M Stover; Rebecca M Saracino; Lauren J Rogak; Sarah T Jewell; Konstantina Matsoukas; Yuelin Li; Ethan Basch
Journal:  Support Care Cancer       Date:  2016-06-03       Impact factor: 3.603

7.  Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study.

Authors:  Kristin Kelly-Pieper; Sangita P Patil; Paula Busse; Nan Yang; Hugh Sampson; Xiu-Min Li; Juan P Wisnivesky; Meyer Kattan
Journal:  J Altern Complement Med       Date:  2009-07       Impact factor: 2.579

8.  Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.

Authors:  M P Michelagnoli; I J Lewis; H R Gattamaneni; C C Bailey; L S Lashford
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Response to imatinib as a function of target kinase expression in recurrent glioblastoma.

Authors:  Marco Ronald Hassler; Mariam Vedadinejad; Birgit Flechl; Christine Haberler; Matthias Preusser; Johannes Andreas Hainfellner; Adelheid Wöhrer; Karin Ute Dieckmann; Karl Rössler; Richard Kast; Christine Marosi
Journal:  Springerplus       Date:  2014-02-25

10.  Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis.

Authors:  Shamudheen M Rafiyath; Mohammad Rasul; Byung Lee; Guoqing Wei; Gurpreet Lamba; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2012-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.